Mycobacterium tuberculosis-induced miR-155 subverts autophagy by targeting ATG3 in human dendritic cells by Etna, Marilena P. et al.
RESEARCH ARTICLE
Mycobacterium tuberculosis-induced miR-155
subverts autophagy by targeting ATG3 in
human dendritic cells
Marilena P. Etna1, Alessandro Sinigaglia2, Angela Grassi3,4, Elena Giacomini1,
Alessandra Romagnoli5, Manuela Pardini1, Martina Severa1, Melania Cruciani1,
Fabiana Rizzo1, Eleni Anastasiadou6, Barbara Di Camillo3, Luisa Barzon2, Gian
Maria Fimia5,7, Riccardo Manganelli2, Eliana M. Coccia1*
1 Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy, 2 Department of Molecular
Medicine, University of Padova, Padua, Italy, 3 Department of Information Engineering, University of Padova,
Padua, Italy, 4 Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy,
5 National Institute for Infectious Diseases "L. Spallanzani”, Rome, Italy, 6 Department of Pathology, Institute
for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United
States of America, 7 Department of Biological and Environmental Science and Technology, University of
Salento, Lecce, Italy
* eliana.coccia@iss.it
Abstract
Autophagy is a primordial eukaryotic pathway, which provides the immune system with
multiple mechanisms for the elimination of invading pathogens including Mycobacterium
tuberculosis (Mtb). As a consequence, Mtb has evolved different strategies to hijack the
autophagy process. Given the crucial role of human primary dendritic cells (DC) in host
immunity control, we characterized Mtb-DC interplay by studying the contribution of cellular
microRNAs (miRNAs) in the post-transcriptional regulation of autophagy related genes.
From the expression profile of de-regulated miRNAs obtained in Mtb-infected human DC,
we identified 7 miRNAs whose expression was previously found to be altered in specimens
of TB patients. Among them, gene ontology analysis showed that miR-155, miR-155* and
miR-146a target mRNAs with a significant enrichment in biological processes linked to
autophagy. Interestingly, miR-155 was significantly stimulated by live and virulent Mtb and
enriched in polysome-associated RNA fraction, where actively translated mRNAs reside.
The putative pair interaction among the E2 conjugating enzyme involved in LC3-lipidation
and autophagosome formation-ATG3-and miR-155 arose by target prediction analysis, was
confirmed by both luciferase reporter assay and Atg3 immunoblotting analysis of miR-155-
transfected DC, which showed also a consistent Atg3 protein and LC3 lipidated form reduc-
tion. Late in infection, when miR-155 expression peaked, both the level of Atg3 and the num-
ber of LC3 puncta per cell (autophagosomes) decreased dramatically. In accordance, miR-
155 silencing rescued autophagosome number in Mtb infected DC and enhanced autolyso-
some fusion, thereby supporting a previously unidentified role of the miR-155 as inhibitor of
ATG3 expression. Taken together, our findings suggest how Mtb can manipulate cellular
miRNA expression to regulate Atg3 for its own survival, and highlight the importance to
develop novel therapeutic strategies against tuberculosis that would boost autophagy.
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Author summary
Mycobacterium tuberculosis (Mtb) is one of the most successful pathogens in human his-
tory and remains the second leading cause of death from an infectious agent worldwide.
The major reason of Mtb success relies on its ability to evade host immunity. Autophagy,
a cellular mechanism involved in intracellular pathogen elimination, is one of the path-
ways hijacked by Mtb to elude the control of dendritic cells (DC), major cellular effectors
of immune response. Recently, it has become clear that Mtb infection not only alters cellu-
lar gene expression, but also controls the level of small RNA molecules, namely micro-
RNAs (miRNAs), which function as negative regulators of mRNA translation into
protein. In the present study, we observed that the infection of human DC with Mtb leads
to a strong induction of host miR-155, a critical regulator of host immune response. By
mean of miR-155 induction, Mtb reduces Atg3 protein content, a crucial enzyme needed
for the initial phase of the autophagic process. Interestingly, miR-155 silencing during
Mtb infection restores Atg3 level and rescues autophagy. These findings contribute to bet-
ter elucidate Mtb-triggered escape mechanisms and highlight the importance to develop
host-directed therapies to combat tuberculosis based on autophagy boosting.
Introduction
As estimated by the 2016 global WHO report, Mycobacterium tuberculosis (Mtb), the causative
agent of tuberculosis (TB) in humans, infects approximately 10 million people each year, mak-
ing TB the second leading cause of death from an infectious disease worldwide [1].
The success of Mtb principally relies on its ability to perfectly adapt to the host, by establish-
ing latent infection and evading from the control driven by immune system. In this scenario,
both innate and adaptive immune responses are required to control TB progression and path-
ogenesis [2].
In particular, the interaction of mycobacteria with antigen-presenting cells (APC) is a key
feature in the pathogenesis of TB and the outcome of this interaction is pivotal in determining
whether immunity or disease would ensue. Human and murine macrophages and dendritic
cells (DC) were shown to be infected by mycobacteria and, in turn, to produce a specific
immune response. As professional APC, DC display indeed an extraordinary capacity to stim-
ulate naïve T cells and initiate primary immune responses [3, 4].
Once in contact with the pathogen, immature DC undergo maturation, modifying their
phenotypic features and producing several pro-inflammatory and regulatory cytokines with
the ability to tune the immune response by acting on different cellular populations [5]. These
events result into a fine control exerted at transcriptional, post-transcriptional and post-trans-
lational level. In turn, host factors, utilized by mycobacterial molecules, play an important role
in the regulation and progression of the infection [6].
In light of these observations, it is conceivable that Mtb infection might not only alter cellu-
lar gene expression but also control important regulators of mRNA translation, such as micro-
RNAs (miRNAs). As a class of small non-coding RNAs, miRNAs are highly conserved within
eukaryotic species and function as key regulators of gene expression by post-transcriptional
targeting of mRNAs for translation arrest or for degradation [7]. These effects are mediated by
imperfect binding of the miRNA-recognition elements within the 3’ untranslated region
(UTR) of the target mRNAs to the miRNA ‘seed’ region located between residues 2–8 at the 5’
end [7].
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In addition to the known role of miRNAs in the multi-level regulation of several cell pro-
cesses and mammalian immune system [7], growing evidences show how pathogens pro-
foundly perturb host miRNA expression. While the involvement of miRNAs in viral immune
responses has been well investigated [8, 9], targeting of host miRNAs by bacterial pathogens is
less characterized. Though, in recent years regulation of miRNA expression has been recog-
nized as a molecular strategy exploited by bacteria to manipulate host cell pathways [10]. In
particular, bacteria may redirect several host cell functions to sustain survival and/or replica-
tion. Most often, these effects require the delivery into the host cytoplasm of bacterial effector
proteins through specific secretion systems [11]. Among closely related bacterial species, the
mycobacterium genus is one of the most effective in inducing differential regulation of miR-
NAs [12, 13].
We set out to identify miRNAs perturbed by Mtb in infected human primary DC and
understand their pathological relevance. We found that in human DC, Mtb induces miR-155
to negatively regulate ATG3, an E2-ubiquitin-like conjugating enzyme involved in autophago-
some formation, thereby impairing autophagy.
Results
Identification of altered miRNAs in Mtb-infected DC
To investigate whether Mtb modulates the immune response by acting on the host DC miR-
Nome, we perfomed a global analysis of miRNA expression profile in human primary DC
infected with Mtb.
RNA was prepared from DC infected in kinetic with live H37Rv Mtb for 3, 8 and 24 hours
and microarray experiment performed. A hierarchical clustering was constructed by consider-
ing only miRNAs whose overall dynamic profile was significantly modulated in Mtb infected
versus uninfected cells (Fig 1). The complete list of the 68 probes differentially expressed, cor-
responding to 43 different miRNAs is shown in Table 1. While only a few miRNAs were
down-regulated as a consequence of Mtb challenge, the majority of them were found up-regu-
lated in Mtb-infected DC (Fig 1). In particular, a high number of miRNAs showed a fold
change (FC) greater than 2, starting from 3 hours post infection and in all the analyzed time-
points, while only two miRNAs, namely miR-548m and miR-548n, were down-regulated with
FC lower than -2 after 24 hours of Mtb infection (Fig 1).
To match our miRNA data with those observed in vivo during TB disease, the list of de-regu-
lated miRNAs identified in infected DC was intersected with the miRNA profile found in
patients affected by active TB [14–28]. Interestingly, among miRNAs de-regulated in TB
patients and validated by real time PCR or similar techniques [14–28], seven miRNAs—namely
miR-155, miR-155, miR-29b-1, miR-150, miR-146a, miR-212 and miR-483-5p –were found
altered in Mtb-infected DC (Figs 1 and 2A). Furthermore, microarray data indicated that Mtb
induced miR-29b-1, miR-150, miR-212 and miR-483-5p at early time points (3 and 8 hours)
(Figs 1 and 2A). MiR-150 and miR-212 induction was maintained over time, while 24 hour
post-infection, miR-29b-1 decreased and miR-483-5p peaked (Fig 2A). Conversely, a different
kinetic of expression was instead observed for miR-146a, miR-155 and its star filament, miR-
155, displaying an increasing level over time during Mtb infection (Fig 2A).
Microarray data were then validated by quantitative PCR analyses (q-PCR) in an indepen-
dent cohort. According to microarray, miR-155, miR-155 and miR-146a were significantly
induced by Mtb during human DC infection in a time dependent manner and, in particular,
miR-155 and its star filament were among the top up-modulated miRNAs in our data set (Fig
2B).
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On the contrary, although miR-29b-1, miR-150, miR-212 and miR-483-5p induction was
confirmed by q-PCR experiments, their kinetic of induction does not perfectly mirror that
showed by microarray analysis (Figs 1 and 2). In particular, the levels of miR-212 and miR-
483-5p induced by Mtb in infected DC and measured by q-PCR are weaker than those
Fig 1. Identification of miRNAs altered in human DC during Mtb infection. DC were infected with Mtb for 3, 8 and 24 hours. Heatmap shows
the significantly regulated miRNAs (FDR<0.05) during infection, in terms of log2 fold changes in the comparison Mtb-infected DC vs. untreated
cells. Each row represents a single miRNA, averaged across different probes if significantly regulated (see Table 1), and each column a different time
point, as indicated. The log2 fold change in the comparison Mtb-infected DC vs. CTRL are represented by a color code according to the legend. The
dendrogram clusters together the significantly regulated miRNAs with most similar expression profiles.
https://doi.org/10.1371/journal.ppat.1006790.g001
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Table 1. List of Mtb de-regulated miRNAs in DC.
probe ID miRNA p-value FDR FC (3 h) FC (8 h) FC (24 h)
A_25_P00010248 hsa-miR-630 5,55E-15 0 15,7 17,4 22,4
A_25_P00010249 hsa-miR-630 8,10E-15 3,12E-12 16,4 17,7 19,2
A_25_P00015143 hsa-miR-1246 3,62E-11 6,96E-09 1,8 6,1 64,7
A_25_P00012271 hsa-miR-155 1,54E-09 1,98E-07 1,2 8,2 29,2
A_25_P00014861 hsa-miR-483-5p 2,08E-09 2,00E-07 3,7 4,2 17,5
A_25_P00015210 hsa-miR-1275 2,47E-09 1,90E-07 6,1 7,2 5,9
A_25_P00013050 hsa-miR-923 4,38E-09 2,81E-07 6,8 7,7 4,3
A_25_P00015036 hsa-miR-320c 5,94E-09 3,27E-07 4,1 5,5 9,1
A_25_P00015195 hsa-miR-1268 6,67E-09 3,21E-07 2,8 2,9 24,5
A_25_P00015107 hsa-miR-1290 6,78E-09 2,90E-07 1,5 4,0 32,5
A_25_P00013051 hsa-miR-923 1,18E-08 4,54E-07 5,8 5,6 5,4
A_25_P00014896 hsa-miR-575 3,49E-08 1,22E-06 5,5 4,1 6,0
A_25_P00011342 hsa-miR-765 4,10E-08 1,31E-06 3,2 4,0 9,9
A_25_P00012270 hsa-miR-155 8,10E-08 2,40E-06 -1,1 4,5 23,9
A_25_P00014921 hsa-miR-1225-5p 1,21E-07 3,31E-06 4,1 4,3 5,6
A_25_P00014920 hsa-miR-1225-5p 1,80E-07 4,63E-06 3,8 4,4 5,3
A_25_P00010808 hsa-miR-575 5,37E-07 1,29E-05 5,7 4,1 2,9
A_25_P00015194 hsa-miR-1268 6,59E-07 1,49E-05 2,7 3,3 7,2
A_25_P00011724 hcmv-miR-UL70-3p 1,01E-06 2,17E-05 3,7 4,7 3,3
A_25_P00011096 hsa-miR-572 1,07E-06 2,16E-05 5,6 3,8 2,6
A_25_P00010402 hsa-miR-638 1,28E-06 2,46E-05 6,3 3,2 2,7
A_25_P00013690 kshv-miR-K12-3 1,86E-06 3,41E-05 6,5 2,9 2,6
A_25_P00012212 hsa-miR-125a-3p 2,28E-06 3,99E-05 2,9 3,4 4,7
A_25_P00015088 hsa-miR-1207-5p 3,49E-06 5,83E-05 4,0 2,6 4,1
A_25_P00012213 hsa-miR-125a-3p 4,41E-06 7,07E-05 2,8 2,5 5,5
A_25_P00013689 kshv-miR-K12-3 5,76E-06 8,87E-05 5,3 2,9 2,5
A_25_P00015075 hsa-miR-1202 7,04E-06 0,00010426 3,0 2,3 5,1
A_25_P00015076 hsa-miR-1202 1,04E-05 0,000148509 3,1 2,4 4,4
A_25_P00015087 hsa-miR-1207-5p 1,16E-05 0,00015901 3,5 2,3 4,0
A_25_P00010403 hsa-miR-638 1,16E-05 0,00015441 5,8 3,2 1,7
A_25_P00011341 hsa-miR-765 1,26E-05 0,000161445 3,4 2,3 3,9
A_25_P00010854 hsa-miR-212 1,84E-05 0,000227877 1,8 2,9 5,3
A_25_P00015303 hsa-miR-1915 2,49E-05 0,00029923 4,9 2,5 2,1
A_25_P00010589 hsa-miR-132 2,59E-05 0,000302001 2,0 3,2 3,9
A_25_P00012899 hsa-miR-886-3p 2,67E-05 0,000301895 1,6 3,0 5,1
A_25_P00015302 hsa-miR-1915 2,95E-05 0,000324597 4,9 2,6 1,9
A_25_P00013941 hsa-miR-125a-3p 8,50E-05 0,000908074 2,0 2,4 3,9
A_25_P00012126 hsa-miR-222 9,00E-05 0,00093585 -1,4 2,9 5,8
A_25_P00010588 hsa-miR-132 0,000113144 0,001145788 2,3 3,0 2,5
A_25_P00012919 hsa-miR-874 0,000123163 0,001215262 1,3 3,2 4,0
A_25_P00013453 hsa-miR-150 0,000157478 0,001515006 1,7 2,5 3,8
A_25_P00010853 hsa-miR-212 0,000167906 0,001575933 2,0 2,5 3,2
A_25_P00012247 hsa-miR-188-5p 0,000187833 0,001720985 2,6 1,5 3,8
A_25_P00014847 hsa-miR-150 0,000350359 0,003135456 3,0 2,0 2,2
A_25_P00012898 hsa-miR-886-3p 0,000642922 0,005622907 1,3 1,4 5,7
A_25_P00015304 hsa-miR-1914 0,000834574 0,007136873 1,6 2,7 2,4
A_25_P00014913 hsa-miR-886-3p 0,000880815 0,007368561 1,7 1,8 3,3
(Continued)
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detected by microarray experiments while miR-29b-1 and miR-150 induction peaked at dif-
ferent time after Mtb infection when measured with the two techniques (Figs 1 and 2).
Functional characteristics of putative targets of selected miRNAs
Since a single miRNA might regulate different mRNAs involved in distinct physiological pro-
cesses, a functional gene ontology (GO) annotation study was conducted to identify those
pathways and processes significantly represented within the list of targets of the seven selected
miRNAs (for complete lists see S1 Table).
In particular, by taking advantage of the performed GO analysis, we noticed that, while
miR-29b-1, miR-150, miR-212 and miR-483-5p showed an enrichment in GO terms im-
portant for host-response to Mtb infection such as ubiquitin, proteasome degradation and
endocytosis, only miR-155, miR-155 and miR-146a displayed a significant enrichment in bio-
logical processes linked to autophagy, a process deeply implicated in Mtb infection control
[29, 30] (S2 Table).
Specific induction of miR-155 expression by live Mtb
Having previously demonstrated that live and virulent Mtb is able to interfere with the autop-
hagy pathway in human DC [29], we compared the expression of miR-155, miR-155 and
miR-146a in DC stimulated with live or heat-inactivated Mtb (HI Mtb), the avirulent BCG vac-
cine, as well as LPS, as positive control (Fig 3).
Table 1. (Continued)
probe ID miRNA p-value FDR FC (3 h) FC (8 h) FC (24 h)
A_25_P00010079 hsa-miR-146a 0,000962151 0,007877726 -1,2 2,5 3,8
A_25_P00013087 hsa-miR-939 0,00131699 0,010558372 2,8 1,2 2,6
A_25_P00012254 hsa-miR-193a-5p 0,001583392 0,012435058 -1,5 3,2 2,4
A_25_P00015250 hsa-miR-1308 0,001598544 0,012302973 2,0 1,6 2,8
A_25_P00013255 hsa-miR-29b-1 0,001775728 0,013398674 1,8 2,7 1,7
A_25_P00013450 hsa-miR-150 0,002594343 0,019199043 2,2 1,5 2,3
A_25_P00015275 hsa-miR-1826 0,002610016 0,018950598 1,2 2,9 2,1
A_25_P00013086 hsa-miR-939 0,002618515 0,018660227 1,8 2,0 2,1
A_25_P00012505 hsa-miR-494 0,002908129 0,020347288 1,9 3,0 1,3
A_25_P00013400 hsa-miR-132 0,003774944 0,025940486 2,0 2,0 1,7
A_25_P00013177 hsa-miR-22 0,00387449 0,02615744 -2,1 2,3 2,1
A_25_P00010769 hsa-miR-195 0,004240248 0,028133179 -2,1 1,1 3,2
A_25_P00013472 hsa-miR-155 0,004934236 0,032182776 1,2 1,7 3,1
A_25_P00013254 hsa-miR-29b-1 0,005170278 0,033160285 1,9 2,4 1,3
A_25_P00013401 hsa-miR-132 0,005214448 0,032895319 2,9 2,1 1,0
A_25_P00015184 hsa-miR-548m 0,006011955 0,037314673 1,3 -1,3 -4,0
A_25_P00015037 hsa-miR-320c 0,006540919 0,039953405 1,7 1,5 2,3
A_25_P00015182 hsa-miR-548n 0,00783043 0,047082686 -1,2 -1,7 -2,8
A_25_P00010078 hsa-miR-146a 0,007850726 0,046478497 1,1 2,4 2,2
A_25_P00012724 hsa-miR-574-5p 0,008522989 0,049693954 2,2 1,5 1,7
List of miRNA probes showing a statistically significant modulation of the overall dynamic profile in Mtb infected DC with respect to uninfected DC. FDR: false
discovery rate; FC: fold change; 3 h: time 3 hours post-infection; 8 h: time 8 hours post-infection; 24 h: time 24 hours post-infection
: miRNA star strand.
https://doi.org/10.1371/journal.ppat.1006790.t001
ATG3 impairment by Mtb-induced miR-155
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006790 January 4, 2018 6 / 30
Fig 2. Validation of miRNAs altered in human DC during Mtb infection. DC were infected with Mtb for 3, 8 and 24 hours. (A) Time-series plots from array data
of miR-155, miR-155, miR-29b-1, miR-150, miR-146a, miR-212 and miR-483-5p are shown. The selected miRNAs are all significantly up-regulated (FDR<0.05)
ATG3 impairment by Mtb-induced miR-155
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While the expression of the three analyzed miRNAs was indistinctly promoted by LPS treat-
ment, we interestingly found a different picture upon stimulation with the mycobacteria (Fig
3). Indeed, BCG and HI Mtb poorly induced miR-155 expression in treated DC as compared
to live Mtb strain, suggesting that the modulation of miR-155 requires stimulation with viru-
lent and live bacterium (Fig 3A). In contrast, miR-155 expression was similarly induced in
response to both live and HI Mtb or BCG (Fig 3B). A different scenario was observed for miR-
146a, induced in DC by all the analyzed stimuli at the different time points with no significant
differences (Fig 3C).
Since the expression of miR-155 was preferentially stimulated by live and virulent Mtb
strain, we focused on this miRNA and further investigated its function in the context of Mtb
infection of human DC.
Localization of Mtb-induced miR-155 into the polysome-associated RNA
fraction
Small RNAs, like miRNAs and RNA not associated with ribosome chains, principally reside in
the light polysome fraction (constituted of monosome and single ribosome subunits), whereas
actively translated mRNAs primarily occupy the heavy polysome fraction (rich in long ribo-
some chains). However, it has been recently shown that miRNAs can be co-purified with poly-
somes and their specific low (light fraction) or high (heavy fraction) polysome occupancy
appears to reflect the strength of interaction with their target mRNAs [31]. Thus, we investi-
gated whether the Mtb-driven miR-155 induction correlates with its localization in heavy poly-
some fraction by digital PCR approach (Fig 4). This allowed us to determine the absolute copy
number of miR-155 in total as well as low and high occupancy polysome-associated RNA sam-
ples in the absence of a reliable housekeeping small RNA.
Interestingly, a 10-fold higher miR-155 copy number was found in total RNA samples from
Mtb-infected DC and this increase was even higher (30-fold) in polysome-associated RNAs.
Few miR-155 copies were instead associated to the light fraction of untreated and Mtb-infected
DC (Fig 4A). As expected, the highest copy number of RNU6b - a commonly used housekeep-
ing small RNA—was found in light fraction irrespective of Mtb infection (Fig 4B). Of note,
after Mtb infection of human DC, the other two mycobacteria-induced miRNAs, namely miR-
146a and miR-155, mainly resided in light associated polysome fraction, although a low num-
ber of copies of those miRNAs was also present in heavy polysome associated RNA samples
(S1 Fig). Taken together, these data indicate that upon Mtb infection the induced miR-155 is
specifically associated with long ribosome chains where it may actively interact with its target
mRNAs.
Identification of ATG3 as a putative target for miR-155
We performed an in silico target prediction analysis of miR-155 by employing and comparing
five different algorithms: Targetscan (http://www.targetscan.org/), Pictar (http://pictar.mdc-
berlin.de/), Diana-microT (http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=
microT_CDS/index), miRanda (http://www.microrna.org/microrna/home.do) and miRwalk
(http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/index.html). In addition to several
during Mtb infection of human DC. When different probes corresponding to the same miRNA were found significant, the mean log2 expression profile across probes
was plotted for the two conditions (CTRL and Mtb). (B) Relative expression of miR-155, miR-155, miR-29b-1, miR-150, miR-146a, miR-212 and miR-483-5p in
human DC left untreated (CTRL) or infected for 3, 8 and 24 hours with wild type Mtb, as measured by q-PCR analysis. Data are derived from 3 healthy donors
independently enrolled from those used for microarray and are normalized to the U6b level using the equation 2-ΔCt. The results shown were mean fold change per
sample ± standard error of the mean at 3, 8 and 24 hours post-infection (p = 0.005; p = 0.02; p = 0.04).
https://doi.org/10.1371/journal.ppat.1006790.g002
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Fig 3. Modulation of miRNA expression in human DC infected with Mtb, BCG vaccine or treated with heat-
inactivated Mtb and LPS. Relative expression of miR-155 (A), miR-155(B) and miR-146a (C) in DC infected with
Mtb or BCG vaccine or treated with heat-inactivated Mtb (Mtb HI) or LPS (1 μg/ml), as measured by q-PCR analysis.
ATG3 impairment by Mtb-induced miR-155
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predicted and, in some case, validated targets of miR-155 [32–34], amongst the miR-155 tar-
gets, all 5 databases identified ATG3, an E2-ubiquitin-like-conjugating enzyme with an essen-
tial role in autophagosome formation [35, 36] (Fig 5A).
To validate the specificity of miR-155-ATG3 mRNA 30-UTR pair interaction, a dual lucifer-
ase assay reporter vector containing the ATG3 30-UTR sequence was transfected in HEK293
cells, together with a miR-155 mimic (hsa-miR-155-5p), a chemically synthesized, double-
stranded RNA, which "mimics” the mature endogenous miR-155. A commercial random
sequence miRNA mimic molecule was used as a negative control mimic. With this setting, a
significant and selective reduction of luciferase activity was observed upon transfection with
the miR-155 mimic, thus confirming a functional interaction between miR-155 and the ATG3
3’-UTR sequence (Fig 5B).
MiR-155-driven reduction of ATG3 level and autophagosome number in
Mtb infected DC
Next, we sought to correlate miR-155 expression with Atg3 protein levels, by studying the
effects of the transfection of miR-155 mimic or negative control elicited in DC. Intriguingly,
miR-155 mimic, but not the scrambled control, caused a dose-dependent reduction of Atg3
protein (about 30–50%), confirming that this enzyme is an authentic miR-155 target in human
primary DC (Fig 5C).
As previously mentioned, Atg3 is an E2-ubiquitin-like-conjugating enzyme with a key
role in the autophagy pathway, which, in a complex with the E1-ubiquitin-like-activating
All quantification data are normalized to the U6b level using the equation 2-ΔΔCt. The results shown were mean fold
change per sample ± standard error of the mean at 3, 8 and 24 hours post-infection of 3 healthy donors independently
enrolled from those used in microarray study. (p = 0.001; p = 0.01; p = 0.02).
https://doi.org/10.1371/journal.ppat.1006790.g003
Fig 4. Mtb-induced miR-155 preferentially combines with polysome-associated mRNAs. Total RNA (Total), low occupancy (Light) and high
occupancy (Heavy) polysome-associated mRNAs were extracted from untreated DC (CTRL) or DC infected for 16 hours with Mtb. (A) MiR-155
and (B) U6b copy number were determined by digital PCR. Data are represented as the mean copy number per sample ± standard error of the
mean of three independent experiments. (p = 0.00003; p = 0.0008; p = 0.00009; p = 0.04).
https://doi.org/10.1371/journal.ppat.1006790.g004
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Fig 5. Identification and biological validation of ATG3 as miR-155 target in DC. (A) MiR-155 putative binding site
in ATG3 3’-UTR region identified by multiple target prediction algorithms. (B) Luciferase assay on HEK293T cells
showing specific targeting of 30-UTR of ATG3 mRNA by the miR-155. Data are represented as the mean fold change
per sample ± Standard Deviation of three independent experiments (p = 0.018). (C) Atg7, Atg3, LC3 and GABARAP
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enzyme Atg7, transfers LC3 or GABARAP proteins to the phosphatidylethanolamine (PE) of
the forming isolation membrane allowing their binding [37]. Accordingly, the low Atg3 pro-
tein abundance in miR-155 mimic-transfected DC correlated with the reduction of LC3-II and
GABARAP (Fig 5C). Although the transfection procedure, requiring nutrient deprivation, per
se promoted LC3 lipidation, a reduction of LC3-II was found only in response to miR-155
mimic transfection, while no effect was observed with the scrambled control. Interestingly, no
variation in the abundance of Atg7 was observed, indicating that LC3-II reduction was strictly
and specifically dependent on miR-155-mediated regulation of Atg3 expression (Fig 5C).
Based on these findings, we next tested if Mtb-induced miR-155 would impair autophago-
some formation by reducing Atg3 protein level and, in turn, affecting the capacity of DC to
convert the autophagosome marker LC3 in its lipidated form. To this end, immunoblot analy-
sis showed a significant decrease in the level of Atg3 24 hours after Mtb infection, which lasted
up to 32 hours (Fig 6A), in tandem with increasing Mtb-driven miR-155 expression (S2 Fig).
The reduction in Atg3 abundance driven by the infection correlated with an impairment of
the lipidated form of LC3 (LC3-II) and GABARAP, particularly at 32 hours post-infection (Fig
6A). Furthermore, while the reduction in LC3 conversion was evident 32 hours post-infection,
Mtb promoted LC3-II accumulation in 24 hour-infected DC, given its well-known ability to
block autophagosome-lysosome fusion [29]. The variation in the abundance of LC3-II
detected by immunoblotting was further confirmed by the significant decrease in the number
of LC3 puncta per cell, as enumerated by confocal microscopy analysis in DC infected for 32
hours with Mtb as compared to those present in 24 hours-infected cells (Fig 6B and 6C).
Since expression of ATG3, LC3 and GABARAP mRNAs was unchanged upon Mtb chal-
lenge (Fig 7A), it is likely that the miR-155 mediated reduction of Atg3 impacts at a post-
transcriptional level on LC3 and GABARAP processing and, in turn, on autophagosome for-
mation. In line with q-PCR data, no variation in ATG3 mRNA copy number was detected by
using digital PCR on total RNA samples from Mtb-infected DC as compared to the untreated
counterpart (CTRL) (Fig 7B). Conversely, association of ATG3 mRNA to high occupancy
polysome chains was significantly induced by Mtb infection as evident from the 2.5 fold induc-
tion of ATG3 expression measured in polysome-associated RNA fraction (Fig 7B). Interest-
ingly, our analysis highlighted that Mtb infection favors the association of both miR-155 and
ATG3 mRNA on polysome chains (Figs 4A and 7B), thus supporting the miR-155-mediated
regulation of ATG3 protein level in DC during Mtb infection.
Rescued autophagosome formation and autolysosome fusion in Mtb-
infected DC by miR-155 silencing
To test whether silencing of Mtb-induced miR-155 impacted on autophagy, Mtb-infected DC
were transfected with a specific inhibitor of miR-155 (α-miR-155 mimic) or with a non-specific
miRNA inhibitor (CTRL mimic) (Fig 8). Silencing efficiency was assessed by analyzing the level
of miR-155 expression in infected cells. An important (75%) reduction was observed only in
the presence of the specific inhibitor (α-miR-155 mimic) (Fig 8A). As expected, by antagonizing
Mtb-induced miR-155 expression in infected DC, the ATG3 protein content was restored at a
level similar to that found in untreated and un-transfected control cells (Fig 8B). Moreover,
protein levels were determined by immunoblotting analysis on un-transfected DC (CTRL) or DC transfected for 24
hours with a miRNA mimic oligonucleotide for miR-155 and with a negative-control miRNA mimic (CTRL mimic).
Band intensity quantification for Atg7, Atg3, LC3 and GABARAP is indicated at the bottom of each immunoblot. Actin
levels were analyzed to verify the amount of loaded proteins. A representative experiment out of three experiments that
yielded similar results is shown.
https://doi.org/10.1371/journal.ppat.1006790.g005
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following the specific inhibition of miR-155, DC recovered their capacity to form autophago-
somes in response to Mtb infection, as demonstrated by the significant increase in the number
of LC3 puncta per cell (Fig 8C and 8D). Notably, the selective silencing of miR-155 in Mtb-
infected DC consistently stimulated the fusion of rescued autophagosomes with lysosomes as
demonstrated by the increased co-localization of the LC3 signal with the lysosomal marker,
LAMP-1, thus, allowing the recovery of the Mtb-blocked autophagic flux (Fig 9).
Fig 6. Mtb down-regulates Atg3 protein level and autophagosome number at later time point of infection. DC were infected with Mtb for 24 and
32 hours or left untreated (CTRL). (A) Atg3, LC3 and GABARAP levels were determined by Western blotting by using specific primary antibodies.
Band intensity quantification is indicated at the bottom of each immunoblot. Actin levels were analyzed to verify the amount of loaded proteins. The
results shown are representative of three independent experiments that yielded similar results. (B) Immunofluorescence analysis of the number of LC3
puncta per cell in Mtb-infected DC. DC were infected with Mtb for 24 and 32 hours or left untreated (CTRL), fixed and then stained with auramine to
color Mtb bacilli (green) and with an anti-LC3 antibody (red). Representative images are shown in panel C. Scale bar 20 μm. (C) Graphic reporting a
quantification of the number of LC3 puncta per cell performed as indicated in Material and Methods. The results represent the mean ± the standard
error of the mean of three independent experiments (p = 0.005; p = 0.003).
https://doi.org/10.1371/journal.ppat.1006790.g006
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Discussion
During their coevolution with the host, successful pathogens, like Mtb, have evolved a myriad
of strategies to evade and, in some cases, subvert innate and adaptive immune responses [6].
These include targeting of autophagy, a cellular mechanism usually devoted to recycle dam-
aged organelles or macromolecules, which also plays a crucial role in counteracting continuous
microbial insults [37]. More specifically, the importance of the autophagic process in host
immune response against Mtb has been demonstrated by the fact that virulent mycobacteria
may impair phagosome maturation by altering the acidic, hydrolytic environment of the intra-
cellular compartment needed to kill the bacteria, thus promoting their own survival [30].
Moreover, the impairment of autophagy machinery compromises antigen-processing capacity
[38, 39] thus, affecting specific host-immune response. Lastly, in Mtb-infected human DC, the
block of autophagosome maturation could be overcame by the autophagy inducer, rapamycin,
which simultaneously boost a protective Th1 response [29].
In spite of the fact that autophagy has been a fast-growing research area in recent years, not
much was known about immune-evasion mechanisms exploited during both viral and
Fig 7. Mtb infection favors ATG3 transcript association with polysome chains in DC. (A) Relative expression of ATG3, LC3 and GABARAP in human
DC infected with Mtb or left untreated (CTRL), as measured by q-PCR analysis on extracted total RNA samples. All quantification data are normalized to
the GAPDH level using the equation 2-ΔCt. The results are the mean fold change per sample ± standard error of the mean at 24 and 32 hours post-infection
of three experiments. (B) Total RNA (Total), low occupancy (Light) and high occupancy (Heavy) polysome-associated mRNAs were extracted from
untreated DC (CTRL) or DC infected for 16 hours with Mtb. ATG3 copy number was determined by digital PCR. Data are represented as the mean copy
number per sample ± standard error of the mean of three independent experiments (p = 0.004).
https://doi.org/10.1371/journal.ppat.1006790.g007
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bacterial infections and acting on the E2-like conjugating enzyme Atg3, critical for LC3 lipida-
tion during autophagosome formation [37]. Here, we show for the first time the capacity of
Mtb to manipulate autophagy, by impairing autophagosome formation, through the host miR-
155-mediated targeting of ATG3 in infected human DC.
The mechanism described in the present study is also in support of the involvement of the
Mtb-triggered de-regulation of host miRNA profile, which, in turn, interferes at post-tran-
scriptional level with the fine-tuned DC gene expression program, crucial for the establish-
ment of an appropriate immunological outcome [13].
In addition to miR-155, we identified several others miRNAs induced in Mtb infected DC,
as miR-155, miR-29b-1, miR-150, miR-146a, miR-212 and miR-483-5p, whose expression
was also found altered in patients affected by pulmonary TB [14–28]. A mechanistic explana-
tion concerning the function of some of these miRNAs along mycobacterial infection has been
already proposed in previous in vitro studies [40–45]. In particular, Mtb stimulates the expres-
sion of miR-29b-1 to target IFN-γ in both NK and CD4+ T cells [40]. A negative regulation of
the TLR2 signaling was instead demonstrated for miR-150 although in the context of BCG
infection [41]. A dual function was shown for miR-146a, which acts on PTGS2, thus increasing
macrophages ability to kill BCG, and reduces TNF-α release by targeting both IRAK1 and
TRAF6 [42, 43]. Finally, several roles were proposed for miR-155 in the context of mycobacte-
rial infection in both innate and adaptive immune cells spanning from maintenance of cell sur-
vival to interference with the autophagy pathway [44–46].
Given the critical role played by autophagy in Mtb infection control [47], we performed a
GO analysis to get insight into the potential functions of Mtb de-regulated miRNAs with a
particular focus on this cellular process. The analysis of putative miRNA target lists revealed a
significant enrichment in autophagy-linked biological processes for three of the selected miR-
NAs, namely miR-155, miR-155 and miR-146a.
Among these miRNAs, we focused our attention on miR-155 because its expression was
specifically induced by live Mtb, and not by HI Mtb or by the vaccine strain BCG. This feature
is particularly interesting in light of our previous data showing that DC differentially respond
to live, dead or attenuated Mtb by promoting the expression of a specific cytokine milieu and
by modulating the autophagic process [5, 29, 48].
Although the potential correlation between miR-155 and mycobacterial infection was
already proposed [13, 17, 32, 44], the presence of miR-155 into the polysome-associated RNA
fraction is a novel finding supporting the idea that in this subcellular localization miR-155 can
engage actively translated mRNA transcripts to specifically control gene expression in Mtb-
infected DC.
Interestingly, data obtained so far in human DC are in support of the interaction between
miR-155 and ATG3 indicated by our in silico target prediction analysis. Indeed, we found a
decrease in Atg3 protein level at late time points of Mtb infection together with the
Fig 8. Silencing of Mtb-induced miR-155 expression restores DC ability to form autophagosome. DC were left untreated (CTRL) or infected
for 8 hours with Mtb at MOI of 1 bacterium/cell and then transfected with 100 nM of an antagomir oligonucleotides for miR-155 (α-miR155
mimic) or with a negative control mimic (CTRL mimic) for 24 hours. (A) Silencing of miR-155 expression was verified by qPCR analysis on total
RNA samples. The results represent the mean ± the standard error of the mean of three independent experiments (p = 0.03). (B) Atg3 protein
levels were determined by immunoblotting analysis. Band intensity quantification for Atg3 is indicated at the bottom of each immunoblot. Actin
levels were analyzed to verify the amount of loaded proteins. The results shown are from one of three experiments that yielded similar results. (C)
Immunofluorescence analysis of the number of LC3 puncta per cell in DC infected with Mtb for 8 hours and then transfected with an antagomir
oligonucleotides for miR-155 (α -miR155 mimic) or with a negative control mimic (CTRL mimic). Thirty-two hours after infection cells were
fixed and then stained with auramine to color Mtb bacilli (green) and with an anti-LC3 antibody (red). Co-localization of LC3 puncta with Mtb
bacilli is indicated by white arrows. A representative image for each condition is shown in panel C. Scale bar 15 μm. (D) Graphics reporting a
quantification of the number of LC3 puncta per cell performed as indicated in Material and Methods. The results represent the mean ± standard
error of the mean of three independent experiments (p = 0.04).
https://doi.org/10.1371/journal.ppat.1006790.g008
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Fig 9. Silencing of miR-155 during Mtb infection recovers DC autophagic flux. DC were infected for 8 hours with Mtb at MOI of 1 bacterium/cell and
then transfected with 100 nM of an antagomir oligonucleotides for miR-155 (α-miR155 mimic) or with a negative control mimic (CTRL mimic) for 24
hours. (A) Immunofluorescence analysis of LC3 and LAMP1 in DC infected with Mtb for 8 hours and then transfected with an antagomir
oligonucleotides for miR-155 (α -miR155 mimic) or with a negative control mimic (CTRL mimic). Thirty-two hours after infection cells were fixed and
then stained with anti-LC3 (red) and anti-LAMP1 (green) antibodies. A representative image for each condition is shown in panel A. Scale bar 15 μm. (B)
Graphics reporting a quantification of the experiment described in A and performed as indicated in Material and Methods. The results represent the
mean ± standard error of the mean of two independent experiments.
https://doi.org/10.1371/journal.ppat.1006790.g009
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impairment of LC3 puncta number per cell. Notably, LPS treatment does not alter LC3-II
level in human DC in spite of its ability to strongly induce miR-155 expression (S3 Fig),
thereby uncovering a previously unidentified Mtb-driven effect of miR-155 on ATG3
expression.
MiR-155-dependent control of ATG3 expression was confirmed by luciferase assay and by
transfection experiments conducted in human primary DC with a specific miR-155 mimic
and showing that miR-155 down-regulates Atg3. This impairment translates into a reduced
ability of the complex Atg7/Atg3 to convert LC3-I in LC3-II and in a diminished capacity to
process the LC3 homologue, GABARAP. Indeed, Atg7, which was not altered as a conse-
quence of miR-155 mimic transfection, activates and transfers LC3-I to the E2-ubiquitin-like-
conjugating enzyme, Atg3, essential for the final conjugation of LC3 to the PE group [49].
These events allow the assembling of the membrane-bound form, LC3-II, to the newborn
autophagosome structures.
Notably, by using an anti-miR-155 mimic, we were able to restore Atg3 protein and its
capacity to form autophagosomes during Mtb infection of human DC. Importantly, the silenc-
ing of miR-155 rescued autophagic flux commonly altered in DC as a consequence of Mtb
infection. These data strongly support the role of miR-155 in controlling the autophagic pro-
cess in human DC and suggest the miR-155/ATG3 axis as a critical component in the manage-
ment of autophagosome formation as well as of the autophagic flux during Mtb infection.
In addition to the mechanism here demonstrated for Atg3 protein, it has been reported that
another autophagy protein involved in autophagosome formation, namely Atg5, has an autop-
hagy-independent protective function in neutrophil-mediated immunopathology during Mtb
infection, however, its role seems to be dispensable in myeloid cells [50].
It was recently demonstrated that the miR-155-mediated regulation of the survival pathway
in innate and adaptive immune cells leads to opposite impacts with regard to Mtb containment
[44]. Accordingly, depending on cell type and stimuli, miR-155 might act as inducer as well as
repressor of the autophagic process [45, 51–53]. Indeed, a pro-autophagic function for miR-
155 was shown by its capacity to target multiple players within the mTOR cascade as Rheb,
although in response to hypoxia or to infection with avirulent Mtb or BCG vaccine [45, 51].
Conversely, Holla and colleagues demonstrated that miR-155 limits IFN-γ-induced autophagy
in murine macrophages infected with BCG or Mtb [52]. This is consistent with a negative role
for miR-155 in human DC infected with Mtb, as proposed in the present study. In line with
this view, it has been suggested that inhibition of this miRNA hinders Mtb survival [53]. This
further underlines that Mtb might induce miR-155 to its own end. Moreover, it was also dem-
onstrated that in addition to miR-155, Mtb engages other miRNAs, such as miR-33 and its star
filament miR-33, to limit the autophagic pathway, whose up-regulation in infected macro-
phages leads to repression of multiple autophagy effector molecules [54]. The notion that Mtb
might use cellular miRNAs to interfere with autophagy process has been also confirmed by
other recent studies showing that Mtb-mediated alteration of miR-125a, miR-17 as well as
miR-144 expression levels undermines the anti-microbial activity of autophagy in infected
macrophages or monocytes [55–57].
Based on these findings, it is clear that Mtb can manipulate the expression of cellular miR-
NAs in order to enhance its survival inside the host and, our study, highlights a novel Mtb-trig-
gered escape mechanism involving cellular miR-155 by which Mtb antagonizes the autophagic
process via a previously unidentified ATG3 reduced expression (Fig 10).
Taken together our data suggest that reconstitution of normal autophagy by antisense miR-
155 molecules could represent an innovative approach for exploiting novel host-directed ther-
apeutic strategy to combat TB.
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Methods
Antibodies (Abs) and other reagents
Monoclonal Abs specific for CD1a, CD14, CD86 (BD Bioscience, San Jose, CA, USA) and Fix-
able Viability Dye (FvDye, eBioscience, San Diego, CA, USA) were used as direct conjugates to
fluorescein isothiocyanate (FITC), phycoerythrin (PE) or eFluor780 as needed.
For immunoblotting analysis, goat anti-Atg7 (Santa Cruz Biotechnologies, Santa Cruz, CA,
USA), rabbit anti-Atg3 (Cell Signaling, Danvers, MA, USA), rabbit anti-GABARAP (Santa
Cruz Biotechnologies), rabbit anti-LC3 (Cell Signaling), mouse anti-actin (Sigma-Aldrich,
St. Louis, MO, USA), and horseradish peroxidase-conjugate secondary anti-goat, anti-mouse
and anti-rabbit Abs (Santa Cruz Biotechnology) were used.
Where indicated, LPS (Sigma-Aldrich) was used at 1 μg/ml.
Ethics statement
Istituto Superiore di Sanità Review Board approved the present research project (CE/13/387).
No informed consent was given since the data were analyzed anonymously. Peripheral blood
Fig 10. Model for Mtb-triggered inhibition of Atg3 activity. Mtb infection of human primary DC causes the strong
induction of hsa-miR-155 expression. The de-regulated miR-155 interacts with the 3’UTR region of the ATG3 mRNA,
leading to a reduced protein level. As a consequence, an impaired LC3 conversion into its lipidated form (LC3-II) through
the addiction of the phosphatidylethanolamine (PE) was observed in Mtb-infected DC.
https://doi.org/10.1371/journal.ppat.1006790.g010
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mononuclear cells were isolated from freshly collected buffy coats obtained from healthy vol-
untary blood donors (Blood Bank of University "La Sapienza", Rome, Italy).
DC preparation and cell culture
DC were prepared as previously described [5]. Briefly, DC were generated by culturing CD14+
monocytes with 50 ng/ml GM-CSF and 1000 U/ml IL-4 (R&D Systems, Minneapolis, MN,
USA) for 5 days at 0.5x106 cells/ml in RPMI 1640 (Lonza, Basel, Switzerland), supplemented
with 2 mM L-glutamine and 15% Fetal Bovine Serum (FBS) (BioWhittaker, #DE14-801F). At
day 5 the cells were tested for their differentiation status by evaluating CD1a expression
(>90% CD1a+) and lack of CD14 (>95% CD14-). Before infection, the medium was replaced
with RPMI without antibiotics and supplemented with 2 mM L-glutamine and 15% FBS. Cyto-
kine deprivation did not affect DC survival rate, which was >90%.
For gene reporter assay, HEK293T cells (5x105 for each condition; a generous gift of Dr.
Kate A. Fitzgerald—University of Massachusetts Medical School, Worcester, MA) were re-sus-
pended in 100 μl DMEM (Lonza) plus 10% FBS (BioWhittaker without antibiotics and plated
in a 96-well plate.
Bacterial strain description and preparation
Mtb H37Rv (ATCC 27294; American Type Culture Collection) was grown as previously
described [5]. Logarithmically growing cultures were centrifuged at 800 rpm for 10 min to
eliminate clumped mycobacteria and then washed three times in RPMI 1640. Mycobacteria
were re-suspended in RPMI 1640 containing 10% FBS and then stored at -80˚C. Bacterial fro-
zen vials were thawed and bacterial viability was determined by counting the number of colony
forming units. All bacterium preparations were tested for endotoxin contamination (<1 Endo-
toxin Unit/ml) by the Limulus lysate assay (Lonza). DC cultures were then infected with a mul-
tiplicity of infection (MOI) of 1 bacterium/cell as previously described [5]. Where indicated,
Mtb was heat-killed at 80˚C for 1 hour.
Total RNA extraction, quantification ad quality assessment
Total RNA was isolated from 1x106 infected or not infected DC using mirVana isolation kit
(Ambion, Thermo Fisher Scientific, Waltham, MA, USA) and following the manufacturer’s
recommendations. An additional phenol/chloroform extraction was performed to inactivate
residual mycobacterial particles. RNA was quantified using a Nanodrop spectrophotometer
(Nanodrop2000, Thermo Fisher Scientific) and quality assessed with an established cut-off of
1.8 for both the 260/280 and 260/270 absorbance ratios. RNA integrity was instead inspected
by bioanalyzer analysis (Agilent Technologies, Santa Clara, CA, USA) considering a cut-off of
1.8 for 28S/18S ratio.
miRNA microarray analysis
Microarray experiments were carried out on the Human miRNA Microarray platform (V3)
(Agilent Technologies). 100 ng of total RNA of experimental sample (infected DC) and of a
reference sample (uninfected DC) was labeled with cyanine Cy3 (miRNA Complete Labeling
and Hybridization Kit, Agilent Technologies). The labeled experimental and reference samples
were denatured and then hybridized on microarray slides containing microRNA capture
probes targeting all human and viral miRNAs listed in the Sanger miRBase database, release
12.0. Each slide was placed in a hybridization chamber (Agilent # G2534A) and hybridized in a
hybridization oven (Agilent # G2545A) for 20 hours at 55˚C. Low- and high-stringency washes
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were carried out and the microarrays were dried following the Agilent washing protocol. A
G2565C microarray scanner (Agilent Technologies) was used to acquire images and Feature
Extraction software version 10.1 (Agilent Technologies) was used to quantify hybridization
signals. Absent and marginal signals, flagged automatically by the software, were removed
from the analysis. Probe intensities were log2-transformed, after adding an offset to accommo-
date zeros according to the formula [x0 = log2(x+1)], where x0 is the adjusted signal and x the
‘total probe signal’ calculated by Feature Extraction software. Normalization was executed
according to the quantile normalization method [58]. Quality assessment was based on both
the Feature Extraction Quality Control reports and the pre- and post-normalization MA plots,
which allow a pairwise comparison of log-intensities of each array to a reference median array
and also the identification of intensity dependent biases. Samples showing a poor reproducibil-
ity of the replicate probes or/and evident trends or saturation effects in the corresponding MA
plots were excluded from the analysis.
To test for miRNA differentially expressed between CTRL and Mtb-infected DC we applied
the “Bounded Area” method [59, 60] to identify the miRNA probesets whose overall dynamic
profile is significantly modulated in Mtb.
Briefly, the area bounded by the miRNA profile with respect to its baseline value was evalu-
ated, and the miRNA was considered differentially expressed if this area exceeded a threshold
θ. θ is the confidence threshold determined in correspondence to a significance level α, based
on the null hypothesis distribution. This latter was derived by repeatedly sampling data from
an error distribution, empirically obtained from the available biological replicates as explained
in [61].
As already shown, the method is quite robust to random oscillation since the entire expres-
sion profile is considered, thus diminishing both false positive and false negative rates with
respect to standard tests when few replicates are available. Moreover, both the precision and
the recall of the test are enhanced by the fact that the entire expression profile is tested, rather
than single time points. In order to account for multiple testing, the significance level α was
corrected for multiple testing so to control the global False Discovery Rate at 5%.
MiRNA microarray data have been deposited in Array Express public repository (https://
www.ebi.ac.uk/arrayexpress/, accession number: E-MTAB-6083) according to the MIAMEs-
tandards. Hierarchical clustering was performed using Euclidean distance and average linkage
method. Bioinformatics analysis was implemented in the R statistical environment.
Isolation of polysome-associated RNA
For RNA fraction isolation, 10x106 cells untreated DC (CTRL) and DC infected for 16 hours
with Mtb (MOI 1) were used. Polysome-associated RNA were prepared as previously
described [62].
Each gradient was fractionated in BSL3 facility by hand collection from the top of the gradi-
ent into 2 samples, light phase (low polysome occupancy) and heavy phase (high polysome
occupancy). The hand collection method was previously tested to parallel with fraction collec-
tion using a fractionator coupled with an UV optical reader (A 254nm). The obtained fractions
were immediately mixed with an equal volume of Trizol (Invitrogen, Thermo Fisher Scientific)
for later RNA isolation following Trizol manufacturing instructions.
Quantitative real time PCR and digital PCR
Total RNA was reverse-transcribed using the TaqMan miRNA reverse transcription kit
(Applied Biosystems, Thermo Fisher Scientific) and miRNA-specific primers (Applied Biosys-
tems, Thermo Fisher Scientific) for hsa-miR-155, hsa-miR-155, hsa-miR-29b-1, hsa-miR-
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150, hsa-miR-146a, hsa-miR-212 and hsa-miR-483-5p. MicroRNA expression levels were then
analyzed using the appropriate TaqMan miRNA assay (Applied Biosystems) and TaqMan
Universal Master Mix II (Applied Biosystems) according to the manufacturer’s instructions.
The ubiquitously expressed U6b snRNA was also quantified as an endogenous control and
used to normalize miRNAs expression by using the equation 2-ΔCt or 2-ΔΔCt as needed. The val-
ues are mean ± SEM of triplicate determinations.
For the analysis of ATG3, LC3 and GABARAP mRNA levels, total RNA was reverse tran-
scribed as previously described [5] and then analyzed using the appropriate TaqMan assay
(Applied Biosystems) and TaqMan Universal Master Mix II (Applied Biosystems) according
to the manufacturer’s instructions. Transcript expression was normalized to the GAPDH level
by using the equation 2-ΔCt; the values are mean ± SEM of triplicate determinations.
Digital PCR experiments were carried out on the BioMark HD System (Fluidigm, San Fran-
cisco, CA, USA) by loading hsa-miR-155 or U6b reverse transcribed samples prepared, as
described previously, from total RNA, light and heavy phase-associated RNA, into Fluidigm’s
37K Digital Array microfluidic chip. Similarly, cDNA samples from total RNA, light and
heavy phase-associated RNA, prepared as previously described [5], were used for ATG3 copy
number determination by digital PCR.
Fluidigm’s 37K Digital Array consists of 48 panels, each of which is further partitioned into
770 reaction chambers. The reaction for each panel was set up with the specific TaqMan
miRNA assay probe and with TaqMan Universal Master Mix II (Applied Biosystems) into a
final volume of 5 μl. For each sample, six serial dilutions were loaded in triplicate reactions and
the chip was then thermocycled and imaged on Fluidigm’s BioMark HD real-time PCR sys-
tem. Positive chambers that originally contained 1 or more molecules has been counted by the
Digital PCR analysis software (Fluidigm) and only templates that yielded 150–360 amplified
molecules per panel were chosen for technical replication in order to obtain absolute quantifi-
cation of miRNA copy number.
Target prediction analysis
For the identification of putative target mRNAs of the selected miRNAs, several prediction
algorithms, namely miRanda (http://www.microrna.org) [63], Targetcan (http://www.
targetcan.org) [64], Pictar5 (http://pictar.mdc-berlin.de/) [65], DIANA-microT (http://diana.
imis.athena-innovation.gr) [66] and miRWalk (http://www.umm.uni-heidelberg.de/apps/zmf/
mirwalk) [67] were used.
Only targets consistently present in all five target-prediction databases were taken into con-
sideration for the study.
Gene ontology analysis
To functionally characterize differentially abundant proteins for biological interpretation,
Gene Ontology (GO) analysis was performed. Gene Ontology annotation for the list of puta-
tive targets of miR-155, miR-155, miR-29b-1, miR-150, miR-146a, miR-212 and miR-483-5p
was obtained from miRWalk (http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk). A two-
tailed Fisher’s Exact Test with Benjamini-Hochberg multiple testing correction was used to
measure the significance of enrichment.
Gene reporter assay
A 174 bp fragment of 30-UTR of ATG3 mRNA, containing the seed sequence (GCATTAA) of
hsa-miR-155-5p was amplified by PCR (forward primer 50- GAGAGAGCTCGAAGAGAGC
ATAAAATCTATCCTAA-30, reverse primer 50-GAGACTCGAGTTTTTATTAAACAAGTA
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AGGCTGG -30). The fragment was designated as ATG3 30-UTR and inserted into the pmir-
GLO Dual-Luciferase miRNA target expression vector (Promega, Madison, WI, USA),
between the SacI and XhoI restriction sites.
The hsa-miR-155-5p mimic was used for transient transfection in gain of function ex-
periments. As a negative control, a random sequence miRNA mimic molecule (Ambion,
Thermo Fisher Scientific), which has been extensively tested in human cell lines and tissues
and validated to not produce identifiable effects on known miRNA function, was employed.
For Dual-Luciferase assay, HEK293T cells (5x105 for each condition) were re-suspended in
100 μl DMEM plus 10% FBS and plated in a 96-well plate.
Lipoplexes were prepared in Opti-MEM serum-free medium (Invitrogen, Thermo Fisher
Scientific) by mixing the constructed plasmids together with hsa-miR-155-5p or negative con-
trol mimics and Lipofectamine 2000 (1mg/ml) (Invitrogen, Thermo Fisher Scientific). Briefly,
400 ng of the pmirGLO Dual-Luciferase miRNA target expression vector plus 5 pmol of spe-
cific miRNA or negative control mimics and 1 μl Lipofectamine 2000 were diluted separately
in 25 μl of Opti-MEM medium. The two solutions were gently mixed and incubated for 5 min-
utes at room temperature and then added to HEK293T cells.
After 24 hours, reporter assay was performed using the kit Dual-Glo Luciferase Assay Sys-
tem (Promega), according to manufacturer’s instructions. Signal of firefly and renilla luciferase
was detected using a Victor X2 reader (Perkin-Elmer, Waltham, MA, USA).
DC transfection
Predesigned miRNA mimic oligonucleotide for hsa-miR-155 was obtained from Ambion
(Thermo Fisher Scientific). A negative-control miRNA mimic [control mimic (Ambion,
Thermo Fisher Scientific)] was used to address the specificity of the observed effect to the spe-
cific miRNA sequence. SiRNA transfection efficiency was determined by transfecting the
BLOCK-iT Fluorescent oligo [a FITC-labeled oligonucleotide (Ambion, Life technologies)]
together with the specific miRNA or negative control at 1:2 ratio using Lipofectamine RNAi-
MAX (Invitrogen, Thermo Fisher Scientific). For each condition, 4x105 DC were pleated in a
12-well plate. Lipoplexes were prepared in Opti-MEM serum-free medium (Invitrogen,
Thermo Fisher Scientific) at 1:1 ratio. Briefly, miRNA mimics plus fluorescent oligonucleotide
and 10 μl of Lipofectamine (1mg/mL) were dilute separately in 250 μl of Opti-MEM medium.
The Lipofectamine solution was added to the miRNA solution and placed for 5 minutes at
room temperature and then added to DC. Four hours after incubation, medium was replaced
with fresh Opti-MEM medium supplemented with 15% FCS and 2 mM L-glutamine for at
least 18 hours. After the indicated time, cells were harvested for transfection efficiency, protein
extraction and RNA isolation from twin wells.
Providing that transfection by itself may perturb DC viability, maturation and activation
[68], preliminary experiments transfecting an oligo-FITC as control of transfection were per-
formed to monitor DC viability, transfection efficiency as well as expression of the co-stimula-
tory molecule CD86 by flow cytometry on a FACS Canto (BD Biosciences) (S4 Fig).
This preliminary setting indicated that transfection did not induce cell mortality (S4A Fig).
Moreover, around 70–75% of viable culture DC resulted to be transfected and, as expected,
CD86 induction was not affected by transfection (S4B Fig and S4C Fig, respectively).
Immunoblotting analysis
For ATG7, ATG3 and GABARAP determination 10 μg of total protein extract were separated
on 10% NuPAGE Bis-Tris gel (Invitrogen, Thermo Fisher Scientific) and electroblotted onto
nitrocellulose membranes (GE Healthcare). For LC3 detection 30 μg of total proteins were
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used for separation on 13.5% NuPAGE Bis-Tris gel and electroblotted onto polyvinylidene
fluoride membranes (GE Healthcare Bio-sciences, Pittsburgh, PA, USA). Blots were incubated
with primary Abs in 5% nonfat dry milk in TBS plus 0.1% Tween20 (Sigma-Aldrich) overnight
at 4˚C. Detection was achieved using horseradish peroxidase-conjugate anti-rabbit, anti-
mouse or anti-goat (Santa Cruz) secondary Abs and visualized with Clarity Western ECL Sub-
strate (Bio-Rad, Segrate, Italy). ATG7, ATG3 and GABARAP quantifications were performed
by calculating their ratio compared to the actin level by using ImageLab software (Bio-Rad).
LC3-II/actin ratio was quantified by ImageLab software according to Klionsky et al [69].
Confocal microscopy
Cells were fixed with 4% paraformaldehyde (Sigma-Aldrich) in PBS followed by permeabiliza-
tion with 0.2% triton X-100 (Sigma-Aldrich) in PBS. Mycobacteria were stained with Aura-
mine for 20 min and decolorized for 10 min. Cells were then labelled with primary antibody
anti-LC3 (Sigma-Aldrich) for 1 hour at room temperature and visualized by means of
Cy3-conjugated secondary Ab (Jackson Immunoresearch, Baltimore, PA, USA). For co-locali-
zation experiments, after fixation, cells were permeabilized with methanol/acetone (1:1)
(Sigma-Aldrich) solution. DC were then labelled with anti-LC3 (Cosmo Bio, Tokio, Japan)
and anti-LAMP1 (Abcam, Cambridge, UK) primary antibodies for 1 hour at room tempera-
ture and visualized respectively by means of Cy3- and Alexafluor 488-conjugated secondary
antibodies (Jackson Immunoresearch).
Coverslips were mounted in SlowFade-Anti-Fade (Invitrogen, Thermo Fisher Scientific)
and examined under a confocal microscope (Leica, Nussloch, Germany). Digital images were
acquired with Leica software and LC3 dots were quantified with Leica Application Suite X
(LAS X) using a set of defined intensity thresholds that were applied to all images. A minimum
of 50 cells per sample was counted for triplicate samples per condition in each experiment.
After image acquisition, the co-localization of LC3 and LAMP-1 signals was examined with
the ImageJ software. Quantification of co-localization, expressed in terms of Mander’s Overlap
Coefficient, was calculated using the JacoP plugin of ImageJ software.
Statistical analysis
Statistical analysis was calculated using a two-tailed Student’s t-test for paired data. A P
value < 0.05 was considered statistically significant.
Supporting information
S1 Fig. Analysis of miR-146a and miR-155 copy number in total as well as low and high
occupancy polysome-associated RNA samples. Total RNA (Total), low occupancy (Light)
and high occupancy (Heavy) polysome-associated mRNAs were extracted from untreated DC
(CTRL) or DC infected for 16 hours with Mtb.
(A) MiR-155 and (B) miR-146a copy number were determined by digital PCR. Data are rep-
resented as the mean copy number per sample ± standard error of the mean of three indepen-
dent experiments.
(TIF)
S2 Fig. Modulation of miR-155 expression at late time points of infection in human DC.
Relative expression of miR-155 in human DC left untreated (CTRL) or infected with wild type
Mtb at MOI 1, as measured by q-PCR analysis on extracted total RNA samples. All quantifica-
tion data are normalized to the U6b level using the equation 2-ΔCt. The results shown were
mean fold change per sample ± standard error of the mean at 8, 24, 32 and 48 hours post-
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infection on RNA samples derived from a set of experiments independent than those used for
microarray (p = 0.03; p = 0.02).
(TIF)
S3 Fig. Modulation of LC3 protein in human DC treated with LPS or infected with Mtb.
LC3 protein levels were determined in human DC left untreated (CTRL), infected with Mtb
for 24 hours or treated with LPS (1 μg/ml) by immunoblotting. Actin levels were analyzed to
verify the amount of loaded proteins. The results shown are representative of three indepen-
dent experiments that yielded similar results.
(TIF)
S4 Fig. Transfection efficiency of human primary DC. DC were left untreated or transfected
for 24 hours with an oligo-FITC and analyzed by flow cytometry. (A) Cell viability was evalu-
ated in DC cultures by staining with the Fixable viability Dye (FvDye). Representative frequen-
cies of live and dead cells are reported in gates. (B) DC transfection efficiency was determined
in live-gated cells by means of an oligo-FITC used as assay control during transfection. (C)
CD86 surface expression was evaluated in live cells in both un-transfected and oligo-FITC-
transfected DC. Mean fluorescence intensity values are shown in each plot.
(TIF)
S1 Table. Complete gene ontology analysis on the list of targets for selected miRNAs
according to biological process. Functional gene ontology (GO) annotation study for biologi-
cal process conducted on the list of putative targets obtained for miRNAs de-regulated in DC
after Mtb infection, namely miR-155-5p, miR-155-3p, miR-29b-1-5p, miR-150-5p, miR-146a-
5p, miR-212-5p and miR483-5p.
(XLSX)
S2 Table. Gene ontology analysis on the list of targets for selected miRNAs according to
biological process linked to autophagy. Functional gene ontology (GO) annotation study for
biological process conducted on the list of putative targets obtained for miRNAs de-regulated
in DC after Mtb infection, namely miR-155-5p, miR-155-3p, miR-29b-1-5p, miR-150-5p,
miR-146a-5p, miR-212-5p and miR483-5p.
The most significant biological process (BP) correlated with the GO terms ‘autophagy/ autop-
hagic/ lysosome/ endocytosis/ endocytic/ ubiquitin’ are shown in the table. GOBPs linked to
autophagy are shown in bold. Only GOBPs showing Fisher’s exact test p-value< 0.05 and Ben-
jamini-Hochberg (BH) corrected p-value < 0.05 were considered for selecting miRNAs
involved in autophagy regulation. ’GOBP-Fg’, ’GOBP-Bg’, ’GenomeFG’ and ’GenomeBG’
stand for ’number of genes predicted as putative targets in a given GOBP’, ’number of genes in
a given GOBP’, ’total number of target genes within genome’ and ’total number of genes
within genome’.
(PDF)
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